Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Korean patients with neurofibromatosis type 1 and plexiform neurofibromas
KCT0003700Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by AstraZeneca. Started May 2019; status: recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on KCT0003700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003700.